3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Sarcoma
5
Rhabdoid Tumor
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Sarcoma, Synovial
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell
3
Wilms Tumor
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Recurrence
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Mesothelioma
2
Medulloblastoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Xanthogranuloma, Juvenile
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibrosarcoma
1
Nerve Sheath Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Inhibition, Psychological
1
Hodgkin Disease
1
Interventions
Nivolumab
4
pertuzumab
2
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Docetaxel
2
Capecitabine
2
ulocuplumab
1
tremelimumab
1
tazarotene
1
talazoparib
1
romiplostim
1
pexidartinib
1
pamiparib
1
onartuzumab
1
magrolimab
1
entrectinib
1
cobimetinib
1
atezolizumab
1
Sunitinib
1
Rifampin
1
Ramucirumab
1
Radiosurgery
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
Midazolam
1
MK-4166
1
LY3022855
1
LY2510924
1
LY-2157299
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Solid Tumor
×
tazemetostat
×
Clear all
No trials found.